Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 


 
 Table of Contents  
CASE REPORT
Year : 2017  |  Volume : 15  |  Issue : 2  |  Page : 131-135

Langerhans cell histiocytosis involving the liver


1 Department of Medicine, CMC, Vellore, Tamil Nadu, India
2 Department of Pathology, University of Michigan, USA
3 Department of Geriatrics, CMC, Vellore, Tamil Nadu, India

Date of Web Publication18-May-2017

Correspondence Address:
Ramya Iyyadurai
Department of Medicine, Christian Medical College, Vellore - 632 004, Tamil Nadu
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/cmi.cmi_19_17

Rights and Permissions
  Abstract 


Langerhans cell histiocytosis is a group of disorders caused by proliferation of the histiocytes. This is a rare neoplastic disease with multisystem involvement. We present a case of an adult male with intermittent fever, recurrent jaundice suggestive of predominant liver involvement. He had undergone multiple courses of anti-tuberculosis treatment with no improvement. Biopsy of the lymph node in our hospital showed Langerhan's cell histiocytosis and liver biopsy showed bridging fibrosis. This case report highlights liver involvement in Langerhans cell histiocytosis with lung and lymph node involvement occurring later, which is an uncommon presentation of this rare disease.

Keywords: Langerhans cell histiocytosis, Langerhans cell histiocytosis prognosis, liver Langerhans cell histiocytosis


How to cite this article:
Iyyadurai R, Asirvatham R, Satyendra S, Surekha V. Langerhans cell histiocytosis involving the liver. Curr Med Issues 2017;15:131-5

How to cite this URL:
Iyyadurai R, Asirvatham R, Satyendra S, Surekha V. Langerhans cell histiocytosis involving the liver. Curr Med Issues [serial online] 2017 [cited 2020 Jul 7];15:131-5. Available from: http://www.cmijournal.org/text.asp?2017/15/2/131/206513




  Introduction Top


Langerhans cell histiocytosis (LCH) is a disease caused by clonal proliferation and migration of dendritic antigen presenting histiocytes. Involvement of the liver in children is well recognized; however, in adults, liver involvement is poorly understood and a cause of severe morbidity and mortality.[1]


  Case Report Top


A 38-year-old grocer from Orissa presented to us in February 2009 with the history of swelling in his neck on the right side associated with intermittent fever and jaundice. He also complained of abdominal distension with vomiting and weight loss of 12 kg since 2006. Fine-needle aspiration cytology of the neck swelling (lymph node) revealed granulomatous inflammation, and he was initiated on anti-tuberculosis therapy (ATT) with rifampicin (450 mg), isoniazid (300 mg), pyrazinamide (750 mg), and ethambutol (600 mg) to be taken once daily.

After 3 months, he was still feeling unwell; hence, he went to a tertiary care hospital where he underwent a barium meal follow through which showed thickened bowel loops and computed tomography scan of the abdomen which showed multiple hypoechoic lesions in the liver. A histopathological examination of biopsy of the hypoechoic lesions in the liver was suggestive of granulomatous hepatitis. He was restarted on nonhepatotoxic antituberculous therapy (injection amikacin 500 mg intravenous once a day, levofloxacin 750 mg once a day, and ethambutol 800 mg once a day) as his transaminase levels were high.

In April 2007 since his symptoms did not improve an upper gastrointestinal endoscopy was done which showed Grade II esophageal varices. He was advised to start taking oral steroids which he took for 1 week and then stopped and came to our hospital for further management. He is neither an alcohol consumer nor a smoker.

At admission in our hospital, the patient was febrile, icteric, and pale. He had a firm, fixed 3 cm × 3 cm right submandibular swelling. His pulse and blood pressure were normal. His liver was enlarged, and his respiratory and cardiovascular examination was normal.

The patient was admitted to the ward where investigations showed deranged liver function tests, deranged bleeding parameters [Table 1], and chest X-ray showed cystic changes in the left lower zone [Figure 1]. Tests done for hepatitis-causing viruses were negative.
Table 1: Investigations

Click here to view
Figure 1: Chest radiograph showing cystic changes in the left lung base.

Click here to view


Differential diagnosis and investigations

At this junction, we considered whether the patient had sarcoidosis, multidrug-resistant tuberculosis (TB) or non-Hodgkins lymphoma (NHL) or LCH since all these illness can cause granulomatous inflammation. Multidrug-resistant TB was considered because the patient had not responded to adequate doses of ATT. Sarcoidosis can involve the liver and causes noncaseating granulomatous inflammation which can involve the lung, liver lymph node. NHL involves the reticuloendothelial system and can cause granuloma formation.

A biopsy of the submandibular lymph node and transjugular liver biopsy was done, after transfusing fresh frozen plasma since the patient had deranged bleeding parameters. The histopathological examination of the liver showed features suggestive of prolonged cholestatic injury with focal periportal bridging and diffuse perisinusoidal fibrosis and Kupffer cell siderosis. A gastroscopy was repeated which showed mild portal gastropathy. Histopathological examination (HPE) of the cervical lymph node showed histiocytes which were CD1a [Figure 2] and [Figure 3] and CD43 positive and for S100 protein, suggestive of an LCH.
Figure 2: Lymph node sections showing strong CD1a staining.

Click here to view
Figure 3: Lymph node sections showing strong SD 100 staining.

Click here to view


Diagnosis, management, and course of illness

Considering that patient had an earlier liver biopsy suggestive of granulomatous inflammation and second liver biopsy showing prolonged cholestatic fibrosis, and lung showing cystic changes with lymph node biopsy suggestive of LCH, a diagnosis of LCH with multisystem involvement was considered. The patient was initiated on high-dose steroids (prednisolone 1 mg/kg). He was also asked to continue his ursodeoxycholic acid (UDCA) and was discharged.

He was symptomatically better with corticosteroids and so went back home. However, he returned to the hospital after 2 months with complaints of hemoptysis. A repeat chest X-ray [Figure 4] followed by a computed tomogram [Figure 5] of the chest showed extensive cystic changes in both the lung bases. Since the patient's disease continued to be active and progressive on oral steroids, he was started on chemotherapy with vincristine.
Figure 4: Chest radiograph showing extensive cystic changes both lung bases.

Click here to view
Figure 5: Computed tomogram showing cystic changes both base.

Click here to view


After three cycles of chemotherapy, the patient developed high-grade fever and cough with purulent expectoration. He was found to have hypotension, and a right-sided pneumonia and required management in the Intensive Care Unit with mechanical ventilation, ionotropic support, and broad spectrum antibiotics. He deteriorated very rapidly and expired.


  Discussion Top


LCH is a group of disorders of unknown origin with a widely variable clinical presentation and outcome. Although known by various terms including histiocytosis X, eosinophilic granuloma, Letterer–Sewe disease, Hand–Schüller–Christian syndrome, the currently preferred name for these group of diseases is LCH.[2] The estimated incidence of LCH is one to two cases per 1 million, being more common between the ages of 21 and 69 with an average age of 32 years.[3]

LCH can be classified as a single-system disorder or multisystem disorder. Single-system LCH involves any one of these areas; bone, skin, lymph node, lungs, or rarely the thyroid or thymus. In multisystem LCH, there is involvement of two or more organs. Individuals with multisystem LCH are further subdivided into low-risk and high-risk categories on the basis of the “risk organs” involved. Involvement of liver, spleen, and bone marrow (considered “risk organs”) in LCH and are associated with a poor prognosis.[4]

In adults, bone is the most commonly involved organ (80% of cases). Extraosseous sites most commonly involved are the hypothalamic-pituitary axis and the skin in 50% of patients, lymph nodes in 10%. Lung involvement is frequent in multisystem disease but seen in only 5% of all patients while the liver and spleen involvement are seen in 1% of the patients. Liver involvement is usually seen in the later stage of the disease or is associated with a more fulminant disease process as seen in our patient. Failure to control the disease in early stages can lead to liver fibrosis or biliary cirrhosis.[2]

The presence of poor prognostic factors [Table 2] is associated with frequent relapses and increased mortality [2] while pituitary involvement is considered to provide survival benefits.
Table 2: Poor Prognostic factors in Langerhans cell histiocytosis

Click here to view


The individual in this discussion had elevated thyroid-stimulating hormone (TSH) and low T3 and T4 levels. Thyroid involvement in LCH is extremely rare. Most cases have an anterior pituitary syndrome with secondary hypothyroidism which presents as low TSH, low T3, and low T4. Patients with thyroid involvement in LCH present with diffuse thyroid swelling. Thyroid involvement may rarely precede multisystem involvement.[5] This individual had thyroid swelling and may have had thyroid involvement which we were not able to prove by biopsy.

The definitive diagnosis of LCH is based histological examinations and histochemical staining. Literature has shown that S100 protein positivity, Ki-67 immunostaining is helpful in diagnosis, and CD1a is considered the most specific marker for LCH.[6] While CD1a the most specific marker was positive in our patient, S100 was negative.

Liver involvement in Langerhans cell histiocytosis

Involvement of the liver in LCH is frequent but often missed. The most common histological finding is sclerosing cholangitis. The initial biochemical tests usually reveal cholestasis with transaminitis. There appears to be two stages in the progression of LCH - an early stage with infiltration of the liver with histiocytes and a late stage where there is sclerosis of the biliary tree.[7] The previous studies show that liver involvement has a negative impact on patient survival. There are no studies on therapy for liver involvement in LCH, but UDCA has been suggested for relief of symptoms.[8] Histopathological examination of the liver in the patient discussed also showed features of prolonged cholestatic injury. The presence of CD1a will help in identifying liver involvement, especially if the liver biopsy is done in late stages and shows only fibrosis [9] as in this patient.

Treatment of Langerhans cell histiocytosis

Treatment of individuals with LCH depends on the extent of the disease and the organ systems involved. Skin lesions and single bony lesions tend to resolve spontaneously. Steroids may help to slow or even stop the progression of disease. In lung LCH, smoking cessation is crucial to prevent disease recurrence or progression. However, for severely symptomatic disease, in which there are complications associated with vital organ dysfunction involving the liver, lungs, and central nervous system, the use of a variety of immunosuppressive treatments have been suggested. Chemotherapeutic agents, such as vinblastine, methotrexate, cyclophosphamide, etoposide, and cladribine, have been used with limited success in patients with progressive disease unresponsive to corticosteroids and in those with multiorgan involvement.[4] The treatment of hepatic LCH consists of systemic chemotherapy, but the therapy is not effective once cirrhosis develops. In patients with advanced liver involvement, liver transplantation is a curative option.[8],[10]

There are no randomized trials in the management of LCH. The current practice is to use cytarabine 100 mg/m [2]. This regiment is considered to be more effective (complete remission in 80%) than cladribine or vincristine/prednisolone which was used in our patient.[11]

Recent studies have identified newer marker for LCH such as BRAF, V600E, and MAP2K1. These markers can identify high-risk patients. They have also been used to develop targeted therapy and newer drugs such as vemurafenib, which is a BRAF inhibitor.[12],[13]

Langerhans cell histiocytosis and tuberculosis

Diagnosis may be missed and needs a high index of clinical suspicion, especially in patients who have been diagnosed to have TB based on granulomatous inflammation of multiple organs and who do not respond to antituberculous therapy. Studies in individuals with pulmonary TB show that sputum conversion occurs at a median of 5.5 weeks and maximum at 6 weeks.[14] If this can be extrapolated to patients with disseminated TB, then it can be assumed that patients with TB of other organ systems are expected to improve by 6 weeks. In case, the clinician does not see clinical improvement then an alternative diagnosis should be suspected and in a patient who does not improve with adequate ATT an alternative diagnosis must be considered. Referral to a higher center where additional HPE techniques are available may lead to diagnosis and appropriate care.


  Conclusions Top


Diagnosis of LCH is difficult since it is a rare illness and it requires special staining techniques. Even if the patient presents with hepatitis as in our patient involvement of the liver is often missed in patients with systemic LCH. Liver involvement is associated with adverse outcomes. Liver biopsy with appropriate histochemical tests such as CD1a is the cornerstone in diagnosis. It is very important to identify liver involvement early for improved outcomes. UDCA is an adjuvant to treatment and patients who present late with liver involvement may require liver transplantation.

In countries like India, where TB is endemic, a person who is suspected of TB based on granulomatous inflammation of multiple organs and started on ATT should be evaluated for other causes, especially when adequate response to ATT does not occur within the expected time frame.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
  References Top

1.
Araujo B, Costa F, Lopes J, Castro R. Adult langerhans cell histiocytosis with hepatic and pulmonary involvement. Case Rep Radiol 2015;2015:536328.  Back to cited text no. 1
[PUBMED]    
2.
Glotzbecker MP, Carpentieri DF, Dormans JP. Langerhans cell histiocytosis: Clinical presentation, pathogenesis, and treatment from the LCH research group at the children's hospital of Philadelphia. Univ PA Orthop J 2002;15:67-73.  Back to cited text no. 2
    
3.
Savva-Bordalo J, Freitas-Silva M. Langerhans cell histiocytosis involving the liver of a male smoker: A case report. J Med Case Rep 2008;2:376.  Back to cited text no. 3
    
4.
Braier JL, Rosso D, Latella A, Chantada G, Ozuna B, Ripoli M, et al. Importance of multi-lineage hematologic involvement and hypoalbuminemia at diagnosis in patients with “risk-organ” multi-system Langerhans cell histiocytosis. J Pediatr Hematol Oncol 2010;32:e122-5.  Back to cited text no. 4
    
5.
Yap WM, Chuah KL, Tan PH. Langerhans cell histiocytosis involving the thyroid and parathyroid glands. Mod Pathol 2001;14:111-5.  Back to cited text no. 5
    
6.
Dina I, Copaescu C, Herlea V, Wrba F, Iacobescu C. Liver involvement in Langerhans' cell histiocytosis. Case report. J Gastrointestin Liver Dis 2006;15:57-9.  Back to cited text no. 6
    
7.
Abdallah M, Généreau T, Donadieu J, Emile JF, Chazouillères O, Gaujoux-Viala C, et al. Langerhans' cell histiocytosis of the liver in adults. Clin Res Hepatol Gastroenterol 2011;35:475-81.  Back to cited text no. 7
    
8.
Buza N, Haque S. Langerhans cell histiocytosis in liver: Single organ involvement in a child. South Med J 2004;97:S64.  Back to cited text no. 8
    
9.
Favara BE. Histopathology of the liver in histiocytosis syndromes. Pediatr Pathol Lab Med 1996;16:413-33.  Back to cited text no. 9
    
10.
Griffiths W, Davies S, Gibbs P, Thillainayagam A, Alexander G. Liver transplantation in an adult with sclerosing cholangitis due to Langerhans cell histiocytosis. J Hepatol 2006;44:829-31.  Back to cited text no. 10
    
11.
Cantu MA, Lupo PJ, Bilgi M, Hicks MJ, Allen CE, McClain KL. Optimal therapy for adults with Langerhans cell histiocytosis bone lesions. PLoS One 2012;7:e43257.  Back to cited text no. 11
    
12.
Harmon CM, Brown N. Langerhans cell histiocytosis: A clinicopathologic review and molecular pathogenetic update. Arch Pathol Lab Med 2015;139:1211-4.  Back to cited text no. 12
    
13.
Dietrich S, Glimm H, Andrulis M, von Kalle C, Ho AD, Zenz T. BRAF inhibition in refractory hairy-cell leukemia. N Engl J Med 2012;366:2038-40.  Back to cited text no. 13
    
14.
Parikh R, Nataraj G, Kanade S, Khatri V, Mehta P. Time to sputum conversion in smear positive pulmonary TB patients on category I DOTS and factors delaying it. J Assoc Physicians India 2012;60:22-6.  Back to cited text no. 14
    


    Figures

  [Figure 1], [Figure 2], [Figure 3], [Figure 4], [Figure 5]
 
 
    Tables

  [Table 1], [Table 2]



 

Top
 
 
  Search
 
Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

 
  In this article
Abstract
Introduction
Case Report
Discussion
Conclusions
References
Article Figures
Article Tables

 Article Access Statistics
    Viewed1976    
    Printed72    
    Emailed0    
    PDF Downloaded42    
    Comments [Add]    

Recommend this journal


[TAG2]
[TAG3]
[TAG4]